3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
28
Gastrointestinal
21
Thoracic
15
Gynecologic
15
Genitourinary
11
Other hematologic neoplasm
10
Tumor-Agnostic
9
Lymphoid
9
Other solid neoplasm
7
Other
7
Dermatologic
5
Sarcoma
4
Head & Neck
4
Plasma cell
2
Other neoplasm
2
CNS
2
Myeloid
1
Endocrine
1
Conditions
Neoplasms
1
Carcinoma, Neuroendocrine
1
Interventions
Everolimus
32
Octreotide
15
Cisplatin
14
pasireotide
13
Sunitinib
13
Temozolomide
11
pembrolizumab
10
Etoposide
10
Doxorubicin
10
lanreotide
9
Magnetic Resonance Spectroscopy
9
Bevacizumab
9
lutetium Lu 177 dotatate
8
gallium Ga 68 dotatate
8
Sorafenib
8
Paclitaxel
8
3-Iodobenzylguanidine
8
lenvatinib
7
pazopanib
6
Radiotherapy
6
Positron Emission Tomography Computed Tomography
6
surufatinib
5
cabozantinib
5
avelumab
5
Thyrotropin Alfa
5
Surgical Procedures, Operative
5
Radiosurgery
5
Nivolumab
5
Mitotane
5
Irinotecan
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Methods
×
Endocrine
×
Clear all
NCT04478175
2022-11-17
DParcoursDig
Institut Curie
Phase NA
Completed
30 enrolled